GRIK1 and central nervous system cancer: Using the highly selective GluK1-inhibitor topiramate (TPM) [76] or establishing novel subunit-specific KAR inhibitors such as piperazine-2,3-dicarboxylic acid derivatives [77], future studies are needed to focus on the role of KARs in glioma progression and glioma-associated epilepsy.